Maiva Pharma has raised Rs 1,000 crore from Morgan Stanley Private Equity Asia and India Life Sciences Fund, including both primary and secondary funding. The funds will be used to set up a new manufacturing facility near Karnataka's Hosur, with capabilities in sterile dosage forms, including pre-filled syringes, bags, oncology, and hormonal injectables. Maiva's complex injectables development and manufacturing capability, strong compliance and regulatory standards, and transparency differentiate the company from competitors. Read The Rest at :